PlaCEUS: Feasibility Study of Contrast-enhanced Ultrasound to Visualize Maternal Uterine Spiral Arteries Postpartum.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorMaxima Medical Center

About this trial

During pregnancy, unique blood vessels form within the uterine wall, known as spiral arteries. These vessels originate from the uterine artery, which is the main artery supplying blood to the uterus. Throughout pregnancy, spiral arteries undergo significant changes to increase blood and oxygen flow to the placenta, ensuring the developing baby receives adequate nutrients. When these arteries fail to remodel properly, complications such as pre-eclampsia or fetal growth restriction can occur.

Until now, direct observation and evaluation of spiral arteries during pregnancy has not been feasible. Contrast-enhanced ultrasound may provide a breakthrough in this area. In this study, the investigators aim to use this imaging technique to visualize spiral arteries after the placenta has been delivered. If successful, this could allow to assess their structural quality. Additionally, the investigators will employ ultrasound to monitor physiological changes in the uterine artery during late pregnancy (after 37 weeks), during labour, and postpartum.

By conducting these measurements, the investigators hope to develop methods for detecting spiral artery abnormalities earlier in pregnancy. Early identification could enable timely interventions and help prevent severe complications.

Eligibility criteria

Qualifiers

Pregnant patient at a minimum age of 18 years

Singleton pregnancy at term (≥37 weeks gestation)

Planning to deliver at the Máxima Medical Centre

Able to provide informed consent

Disqualifiers

Multiple gestation pregnancy

Contra-indications to CEUS, e.g. known allergy for constituents of SonoVue™

Planning on breastfeeding

Medical emergency during or after delivery, which makes CEUS impossible or undesirable

Trial design

Treatments tested in this trial

  • SonoVue (sulphur hexafluoride microbubbles)

Treatment groups

5 Participants
are divided into 1 treatment group

Sponsors and collaborators